Hengrui and Braveheart Present 52-Week Data for HRS/BHB-1893
Biotechnology
Business Update
IPO:
Aug 06, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Hengrui Pharma and Braveheart Bio Present 52-Week Phase 2 Data for HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
Shanghai and San Francisco, USA - Hengrui Pharma (SSE: 600276; HKEX: 1276) and Braveheart Bio (NASDAQ: BRVE) presented new data from a 52-week open-label extension of the Phase 2 study evaluating the next-generation cardiac myosin inhibitor HRS/BHB-1893 in patients with obstructive hypertrophic cardiomyopathy (oHCM). The findings were shared at the American Heart Association Scientific Sessions 2026.
... Read on — Members only
About Braveheart Bio, Inc.
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui”) in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui (the “Exclusive License Agreement”), and as such, all clinical trials of BHB-1893 completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial conducted in Australia. We were not involved in the design, conduct, or oversight of these trials.
